On March 18, 2022, Pfizer filed a 45 page opposition to the KEI application for a compulsory license on Paxlovid patents in the Dominican Republican. This is the Pfizer filing, and KEI’s unofficial translation. Pfizer-opposition-DR-CL-18March2022.pdf Translation-Pfizer-opposition-KEI-CL-Paxlovid-18march2022.pdf The December 3, 2021… Continue Reading →
Following the publication of the US government contract with Pfizer for the COVID-19 therapeutic Paxlovid, the petitioners of the Xtandi government use request wrote to the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH)… Continue Reading →
Published in an article by Sydney Lupkin of NPR, the Pfizer-US government contract for the COVID-19 therapeutic Paxlovid contains terms of interest in broader drug pricing discussions. The Pfizer contract includes a “Most Favored Nation Clause” (H.7), which provides that… Continue Reading →
MPP Pfizer license Dominican Republic compulsory licensing case.
On Friday, December 3, 2021, KEI requested an open public interest license to allow the exploitation of PF-07321332 (marketed in combination with ritonavir under the brand Paxlovid) in the Dominican Republic. PF-07321332, being developed by Pfizer, has shown promising results… Continue Reading →
USTR-AmbTai-Bilateral-Plurilateal-agreements-3Dec2021 December 3, 2021 Ambassador Katherine Tai Office of the United States Trade Representative Washington, DC Dear Ambassador Tai, On November 18, 2021, Knowledge Ecology International (KEI) provided comments to USTR on three issues that were important for any WTO… Continue Reading →
On November 16, 2021, Pfizer and the Medicines Patent Pool (MPP) announced at voluntary license to patented inventions and know-how to manufacture a two drug combination to treat COVID-19. The MPP announcement is here and here. Additional comments on the… Continue Reading →
On September 22, 2021, Knowledge Ecology International (KEI) obtained a copy of the $3.5 billion contract between the U.S. government and Pfizer to purchase 500 million doses of the Pfizer/BioNTech vaccine for international donation to low- and middle-income countries. The… Continue Reading →
The $10 billion contract between the U.S. government and Pfizer to purchase 500 million doses of the Pfizer COVID-19 vaccine contains a clause indicating that the $20 per dose price may be a floor and not a ceiling going forward.… Continue Reading →
On March 1, 2021, KEI obtained a copy of the binding term sheet between Pfizer/BioNTech and the Dominican Republic for the supply of their COVID-19 vaccine in the country. The document, requested via the freedom of information law in the… Continue Reading →